Tim Chiang
Stock Analyst at Capital One
(1.09)
# 3,754
Out of 5,182 analysts
20
Total ratings
33.33%
Success rate
-5.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Chiang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HRTX Heron Therapeutics | Initiates: Overweight | $6 | $0.83 | +621.15% | 1 | Apr 23, 2024 | |
| PTGX Protagonist Therapeutics | Initiates: Overweight | n/a | $102.09 | - | 3 | Oct 30, 2023 | |
| JSPR Jasper Therapeutics | Initiates: Overweight | $70 | $0.71 | +9,799.59% | 1 | Aug 11, 2023 | |
| AMPH Amphastar Pharmaceuticals | Initiates: Overweight | $44 | $20.40 | +115.69% | 2 | Jul 29, 2022 | |
| KALA KALA BIO | Maintains: Outperform | $300 → $200 | $0.18 | +112,385.94% | 2 | Mar 30, 2022 | |
| PCRX Pacira BioSciences | Maintains: Market Perform | $75 → $66 | $23.25 | +183.87% | 3 | May 5, 2021 | |
| VRCA Verrica Pharmaceuticals | Initiates: Outperform | $210 | $5.82 | +3,508.25% | 1 | Jun 24, 2020 | |
| TEVA Teva Pharmaceutical Industries | Upgrades: Neutral | n/a | $30.52 | - | 6 | Sep 17, 2018 | |
| SMMT Summit Therapeutics | Initiates: Buy | $33 | $18.81 | +75.44% | 1 | Feb 13, 2018 |
Heron Therapeutics
Apr 23, 2024
Initiates: Overweight
Price Target: $6
Current: $0.83
Upside: +621.15%
Protagonist Therapeutics
Oct 30, 2023
Initiates: Overweight
Price Target: n/a
Current: $102.09
Upside: -
Jasper Therapeutics
Aug 11, 2023
Initiates: Overweight
Price Target: $70
Current: $0.71
Upside: +9,799.59%
Amphastar Pharmaceuticals
Jul 29, 2022
Initiates: Overweight
Price Target: $44
Current: $20.40
Upside: +115.69%
KALA BIO
Mar 30, 2022
Maintains: Outperform
Price Target: $300 → $200
Current: $0.18
Upside: +112,385.94%
Pacira BioSciences
May 5, 2021
Maintains: Market Perform
Price Target: $75 → $66
Current: $23.25
Upside: +183.87%
Verrica Pharmaceuticals
Jun 24, 2020
Initiates: Outperform
Price Target: $210
Current: $5.82
Upside: +3,508.25%
Teva Pharmaceutical Industries
Sep 17, 2018
Upgrades: Neutral
Price Target: n/a
Current: $30.52
Upside: -
Summit Therapeutics
Feb 13, 2018
Initiates: Buy
Price Target: $33
Current: $18.81
Upside: +75.44%